-
1
المؤلفون: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
المساهمون: University of Zurich
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 13
Dummer, R, Long, G V, Robert, C, Tawbi, H A, Flaherty, K T, Ascierto, P A, Nathan, P D, Rutkowski, P, Leonov, O, Dutriaux, C, Mandalà, M, Lorigan, P, Ferrucci, P F, Grob, J J, Meyer, N, Gogas, H, Stroyakovskiy, D, Arance, A, Brase, J C, Green, S, Haas, T, Masood, A, Gasal, E, Ribas, A & Schadendorf, D 2022, ' Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology . https://doi.org/10.1200/JCO.21.01601Testمصطلحات موضوعية: Proto-Oncogene Proteins B-raf, Adult, Cancer Research, Skin Neoplasms, Adolescent, Pyridones, Clinical Trials and Supportive Activities, Clinical Sciences, Oncology and Carcinogenesis, Medizin, 610 Medicine & health, Pyrimidinones, Antibodies, Death Domain, Clinical Research, Neoplasms, Oximes, Antineoplastic Combined Chemotherapy Protocols, Receptors, Monoclonal, Genetics, Humans, Oncology & Carcinogenesis, Melanoma, Humanized, Cancer, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Human Genome, Imidazoles, Evaluation of treatments and therapeutic interventions, 10177 Dermatology Clinic, Second Primary, Oncology, 6.1 Pharmaceuticals, Mutation
وصف الملف: 928_Dummer_R._et_al._Randomized_Phase_III_Trial_Evaluationg_Spartalizumab_plus_Dabrafenib_and_Trametinib_for_BRAF_V600_mutant_JCO_2022.pdf - application/pdf; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::512e67c5f66bacf61087d7e838e0dc59Test
https://www.zora.uzh.ch/id/eprint/213526Test/ -
2
المؤلفون: Mario Mandalà, Juliette Murris, Paola Queirolo, Ana Arance, Caroline Dutriaux, Helen Gogas, Gabriella Liszkay, Ralf Gutzmer, Claus Garbe, Keith T. Flaherty, Abir Tadmouri Sellier, Naoya Yamazaki, Jeanne Suissa, Ivana Krajsová, Vanna Chiarion Sileni, Caroline Robert, Reinhard Dummer, Groot Jan de Willem, Paolo A. Ascierto, Ashwin Gollerkeri, Carmen Loquai, Dirk Schadendorf
المساهمون: University of Zurich
مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Skin Neoplasms, Health-related quality of life, Medizin, Hospitalisation rate, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, humanities, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, Open label, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, BRAF(V600E−K) mutant Melanoma, Young Adult, 03 medical and health sciences, BRAF/MEK inhibitors Combination, Internal medicine, medicine, Humans, In patient, Encorafenib plus binimetinib, Aged, business.industry, Repeated measures design, medicine.disease, 030104 developmental biology, chemistry, Mutation, Quality of Life, Benzimidazoles, Carbamates, business
وصف الملف: 898_Gogas_H._et_al._Quality_of_life_in_patients_with_BRAF_mutant_melanoma_receiving_the_combination_encorafenib_plus_binimetinib_EJC_2021.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47bTest
https://www.zora.uzh.ch/id/eprint/203982Test/ -
3
المؤلفون: Keith T. Flaherty, Laure Moutouh-de Parseval, Michael D Pickard, Carmen Loquai, Victor Sandor, Naoya Yamazaki, Ivana Krajsová, Gabriella Liszkay, Reinhard Dummer, Dirk Schadendorf, Mario Mandalà, Ana Arance, Ralf Gutzmer, Claus Garbe, Paolo A. Ascierto, Helen Gogas, Caroline Robert, Jan Willem de Groot, Caroline Dutriaux, Vanna Chiarion Sileni
المساهمون: University of Zurich, Dummer, Reinhard
المصدر: The Lancet Oncology. 19:1315-1327
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Time Factors, Medizin, Phases of clinical research, Gene mutation, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Trametinib, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, Phenotype, Tolerability, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Progression-free survival, Protein Kinase Inhibitors, Aged, Performance status, business.industry, 030104 developmental biology, chemistry, Mutation, Benzimidazoles, Carbamates, business
وصف الملف: 775_Dummer_R._et_al._Overall_survival_in_patients_with_BRAF-mutant_melanoma_receiving_encorafenib_plus_Lancet_Oncol._2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb4f4dc2694f231c2c21cb1932e261Test
https://doi.org/10.1016/s1470-2045Test(18)30497-2 -
4
المؤلفون: Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob
المساهمون: HAL UVSQ, Équipe, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Service de dermatologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, Université de Lille, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Léon Bérard [Lyon], Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Service de Dermatologie [CHU Limoges], CHU Limoges, Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Novartis Pharma S.A.S., CHU Bordeaux [Bordeaux], Amgen, Bristol-Myers Squibb, BMS, Pfizer, Merck, Novartis, Roche, Sanofi, Meso Scale Diagnostics, MSD, Novartis Pharma, Les Laboratories Pierre Fabre, This work was supported by Novartis Pharma S.A.S. , France., Philippe Saiag has received personal fees from Amgen, Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, Sanofi and Novartis, he has received non-financial support from Bristol-Myers Squibb, MSD, Roche-Genentech and Novartis, and has received a funding grant from Roche-Genentech., Céléste Lebbe has received honoraria from BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte, has acted as a consultant or has served as a member of an advisory board for BMS, and has received travel grant support from BMS and MSD., Jean-Jacques Grob has received honoraria from BMS, MSD, Merck, Pfizer, Incyte, Novartis, Roche, Amgen and Pierre Fabre, has received travel grant support from BMS, MSD and Roche, and has acted as a consultant and advisor for BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
المصدر: European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, Cancer Research, medicine.medical_specialty, Pyridones, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pyrimidinones, 030204 cardiovascular system & hematology, Regression tree, 03 medical and health sciences, BRAF V600-mutation, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Trametinib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Prospective Studies, Stage (cooking), Prospective cohort study, education, neoplasms, Melanoma, Aged, Neoplasm Staging, education.field_of_study, Proportional hazards model, business.industry, Dabrafenib, Imidazoles, Middle Aged, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Female, business, Brain metastasis, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2Test
https://hal.science/hal-03401780Test -
5
المؤلفون: Shannon Marshall, Alain Algazi, Sunandana Chandra, Caroline Robert, Nancy Mueller, Leonel Hernandez-Aya, Wilson H. Miller, Jose Lutzky, Marcus O. Butler, Michael D. Gordon, Paolo A. Ascierto, Antoni Ribas, Bruno Delafont, Katie M. Campbell, Donald P. Lawrence
المصدر: Nature communications, vol 11, iss 1
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Durvalumab, Skin Neoplasms, General Physics and Astronomy, B7-H1 Antigen, Cohort Studies, 0302 clinical medicine, Oximes, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, Melanoma, Cancer, Trametinib, Aged, 80 and over, Multidisciplinary, MEK inhibitor, Imidazoles, Antibodies, Monoclonal, Middle Aged, Progression-Free Survival, Tolerability, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Cohort, Female, Mitogen-Activated Protein Kinases, medicine.drug, Cohort study, Diarrhea, Proto-Oncogene Proteins B-raf, Adult, medicine.medical_specialty, Pyridones, Science, Immunology, Clinical Trials and Supportive Activities, Pyrimidinones, Article, General Biochemistry, Genetics and Molecular Biology, Antibodies, 03 medical and health sciences, Young Adult, Clinical Research, Internal medicine, medicine, Humans, Author Correction, neoplasms, Aged, business.industry, Evaluation of treatments and therapeutic interventions, Dabrafenib, General Chemistry, Exanthema, medicine.disease, 030104 developmental biology, Mutation, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::214f5a164c72be16363987dcb81eb292Test
https://escholarship.org/uc/item/344192vkTest -
6
المؤلفون: Ralf, Gutzmer, Daniil, Stroyakovskiy, Helen, Gogas, Caroline, Robert, Karl, Lewis, Svetlana, Protsenko, Rodrigo P, Pereira, Thomas, Eigentler, Piotr, Rutkowski, Lev, Demidov, Georgy Moiseevich, Manikhas, Yibing, Yan, Kuan-Chieh, Huang, Anne, Uyei, Virginia, McNally, Grant A, McArthur, Paolo A, Ascierto
المصدر: Lancet (London, England). 395(10240)
مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate, Middle Aged, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, Progression-Free Survival, Double-Blind Method, Piperidines, Vemurafenib, Antineoplastic Combined Chemotherapy Protocols, Mutation, Azetidines, Humans, Female, Neoplasm Metastasis, Melanoma, Aged, Neoplasm Staging
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::ae0fc6f1503f4e8640866ea2c3ddd337Test
https://pubmed.ncbi.nlm.nih.gov/32798490Test -
7
المؤلفون: Caroline Robert, Jacob Schachter, Thierry Lesimple, C. Dutriaux, Dirk Schadendorf, Monique Tan, Axel Hauschild, Georgina V. Long, R. Dummer, Eduard Gasal, Mario Santinami, Kohinoor Dasgupta, James Larkin, Mario Mandalà, Andrew M. Haydon, John M. Kirkwood, Vanna Chiarion Sileni, Laurent Mortier, Victoria Atkinson, Marta Nyakas, Ruth Plummer
المساهمون: University of Zurich
مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, medicine.medical_treatment, Medizin, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Oximes, Medicine, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, Trametinib, Imidazoles, Follow up studies, 10177 Dermatology Clinic, General Medicine, Middle Aged, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Disease-Free Survival, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Humans, Stage III melanoma, Protein Kinase Inhibitors, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, Survival Analysis, Clinical trial, Mutation, business, Follow-Up Studies
وصف الملف: 848_Dummer_R._et_al._Five-Year_Analysis_of_Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_Melanoma_NEJM_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d710d2b0f671e5dafc838391b9965d4aTest
https://www.zora.uzh.ch/id/eprint/190018Test -
8
المؤلفون: Eduard Gasal, Paul Nathan, Antoni Ribas, Neha Pakhle, Victoria Atkinson, Céleste Lebbé, Dirk Schadendorf, Mario Mandalà, Daniel Gusenleitner, Paolo A. Ascierto, Aisha Masood, Erika Richtig, Catarina D. Campbell, Reinhard Dummer, Ana Arance, Keith T. Flaherty, Hussein Abdul-Hassan Tawbi, Naoya Yamazaki, Georgina V. Long, Caroline Robert, Jan C. Brase
المساهمون: University of Zurich, Dummer, Reinhard
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Skin Neoplasms, Medizin, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Biomarker (medicine), Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Mutation, Missense, 610 Medicine & health, Genetics and Molecular Biology, Pyrimidinones, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Young Adult, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Dabrafenib, medicine.disease, Clinical trial, Regimen, 030104 developmental biology, General Biochemistry, business
وصف الملف: 870_Dummer_R._et_al._Combined_PD-1,_BRAF_and_MEK_inhibition_in_advanced_BRAF-mutant_melanoma_Nature_Medicine_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b17ee96d80a3281cdd7448c58c9110fTest
https://www.ncbi.nlm.nih.gov/pubmed/33020648Test -
9
المؤلفون: Reinhard, Dummer, Jan C, Brase, James, Garrett, Catarina D, Campbell, Eduard, Gasal, Matthew, Squires, Daniel, Gusenleitner, Mario, Santinami, Victoria, Atkinson, Mario, Mandalà, Vanna, Chiarion-Sileni, Keith, Flaherty, James, Larkin, Caroline, Robert, Richard, Kefford, John M, Kirkwood, Axel, Hauschild, Dirk, Schadendorf, Georgina V, Long
المصدر: The Lancet. Oncology. 21(3)
مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Adolescent, Pyridones, Pyrimidinones, Young Adult, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, Oximes, Humans, Neoplasm Metastasis, Melanoma, Aged, Aged, 80 and over, Salvage Therapy, Imidazoles, Middle Aged, Prognosis, Survival Rate, Drug Resistance, Neoplasm, Mutation, Female, Neoplasm Recurrence, Local, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::82f686582204c03888e4020dc478c975Test
https://pubmed.ncbi.nlm.nih.gov/32007137Test -
10
المؤلفون: Vanna Chiarion-Sileni, Ana Arance, Keith T. Flaherty, Ralf Gutzmer, Claus Garbe, Ivana Krajsová, Dirk Schadendorf, Naoya Yamazaki, Caroline Robert, Helen Gogas, Michael D Pickard, Caroline Dutriaux, Laure Moutouh-de Parseval, Jan Willem de Groot, Carmen Loquai, Paolo A. Ascierto, Victor Sandor, Mario Mandalà, Reinhard Dummer, Gabriella Liszkay
المصدر: The Lancet Oncology. 19:603-615
مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, medicine.medical_specialty, Skin Neoplasms, Time Factors, Phases of clinical research, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, Progression-free survival, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Sulfonamides, Performance status, business.industry, MEK inhibitor, Binimetinib, Middle Aged, medicine.disease, Progression-Free Survival, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Mutation, Benzimidazoles, Female, Carbamates, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b9a8d731aee37b91ba57a2467a28bbTest
https://doi.org/10.1016/s1470-2045Test(18)30142-6